Alcobra Ltd. (NASDAQ:ADHD)’s share price traded up 5.2% during trading on Friday . The company traded as high as $4.88 and last traded at $4.86, with a volume of 110,644 shares trading hands. The stock had previously closed at $4.62.

A number of equities analysts have recently commented on the stock. Canaccord Genuity assumed coverage on shares of Alcobra in a research report on Tuesday, June 7th. They issued a “buy” rating for the company. Roth Capital restated a “buy” rating and issued a $12.00 price objective on shares of Alcobra in a research report on Tuesday, June 21st. Zacks Investment Research upgraded shares of Alcobra from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Thursday, April 28th. Finally, Cantor Fitzgerald assumed coverage on shares of Alcobra in a research report on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $10.63.

The company’s market capitalization is $133.95 million. The stock’s 50 day moving average is $4.80 and its 200 day moving average is $4.74.

Alcobra (NASDAQ:ADHD) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. Equities research analysts anticipate that Alcobra Ltd. will post ($0.98) EPS for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.